The purpose of the study is to determine whether adding ASP3082 to chemotherapy can improve overall survival compared with chemotherapy alone. Participants are randomly assigned to one of the two treatment groups and receive study medication and chemotherapy in cycles over several months, with regular check‑ups to monitor health, side effects, and any changes in tumor size. The study follows participants from the start of treatment until its end, recording outcomes and safety information throughout.

Patients will receive an infusion of the assigned medication(s) every few weeks, and the treatment period will continue for several months unless stopped earlier for safety reasons. Throughout the study, doctors will use imaging scans and the criteria called RECIST to measure changes in tumor size and calculate the objective response rate, which reflects the proportion of participants whose tumors shrink or disappear. Safety will be monitored by regular check‑ups, lab tests, and reporting of any side effects. After the treatment phase, participants will be followed for additional time to observe how long any tumor response lasts and overall health outcomes.

The purpose is to see whether adding daxdilimab can lower disease activity compared with placebo. Adults are randomly assigned to receive either the study drug or placebo and neither the participants nor the investigators know which is given (double‑blind). Over about six months, participants attend regular visits where doctors assess improvement using the Total improvement score (a number that shows how much the disease has gotten better) and the CDASI activity score (a measure of skin involvement). Safety is checked at each visit, and blood samples are taken to monitor drug levels and any immune response called antidrug antibodies.

The aim of the trial is to determine whether six cycles of this chemotherapy followed by active surveillance—regular check‑ups without further treatment unless the cancer returns—can extend the time a patient lives without evidence of disease, known as disease-free survival, compared with observation alone. This phase III study randomly assigns eligible patients to either the chemotherapy plus surveillance plan or to surveillance only, then monitors them over several years with routine visits, imaging tests, and quality‑of‑life questionnaires to track any recurrence, side effects, and overall health.

Participants are randomly placed into one of two groups: one receives the standard chemotherapy alone, and the other receives the same chemotherapy plus venetoclax taken by mouth each day for a set period. Treatment cycles are repeated as scheduled, and children are followed for several months to monitor their health. The main result the study looks at is overall survival, which means the length of time from the start of the study until death from any cause.

The purpose of the study is to provide continued access to opnurasib for participants who are still experiencing benefit from the drug.

Participants continue to take the study medication on a regular schedule and visit the clinic for routine check‑ups where doctors look for any side effects and adjust treatment if needed. The study proceeds until the participant and the medical team decide to stop the medication.

The purpose of the study is to compare the effects of Odevixibat with a placebo in children with Biliary Atresia. Participants will receive either Odevixibat or a placebo once daily. The study will last for up to 104 weeks, during which time the health of the participants will be closely monitored. The main focus will be on the time it takes for participants to require a liver transplant or experience other serious health issues related to their liver condition.

Throughout the study, various health parameters will be assessed, including liver function tests and overall health status. The study aims to provide valuable information on whether Odevixibat can help improve the outcomes for children with Biliary Atresia who have had the Kasai procedure. Participants will be regularly checked for any side effects or changes in their health to ensure their safety during the trial.

The main goal is to evaluate the long-term safety of the therapy, meaning researchers will track any unwanted health problems that may appear after treatment. Participants who have already received the infusion will be followed for several years with regular clinic visits, blood draws, and imaging as part of routine care. During these visits, doctors will look for adverse events, monitor whether the disease returns or gets worse, and, for children, assess growth and puberty development. No new medication is given during the follow‑up; the study only observes what happens over time.

The purpose of the study is to find out whether VS-7375 is safe and can help shrink tumors in people with these KRAS‑mutated cancers. Participants will start by taking the tablet alone, with the dose slowly increased under medical supervision, and later may receive the tablet together with the listed IV medicines. They will visit the clinic regularly for physical checks, blood tests, and imaging scans that show the size of the tumor.

Throughout the trial, doctors will watch for any side effects such as nausea, fatigue, or changes in blood counts, and will perform simple heart tests (like an ECG) and laboratory checks. Imaging studies (pictures of the inside of the body) will be used to see if the cancer gets smaller, stays the same, or grows. The information gathered will help decide the best dose and whether the treatment should be studied further.

The purpose of the study is to see whether the new combination is safe and works better than standard chemotherapy. In the first part, doctors will watch for any adverse event (side effect) and will check how many patients achieve a complete response (no signs of cancer left). In the second part, the new treatment will be compared with the usual chemotherapy plus rituximab, and researchers will measure how long patients stay without the cancer getting worse, known as progression‑free survival. Participants will receive treatment cycles every few weeks and will have regular doctor visits, blood tests, and scans to see how the disease is responding.

The purpose is to determine how often the tumors shrink or disappear, expressed as the objective response rate. Participants will be randomly placed into one of the treatment groups and will receive the assigned medication(s) for a set period, with regular medical visits that may include imaging scans evaluated using the RECIST criteria, a standard system doctors use to measure changes in tumor size. Throughout the study, safety will be tracked by recording side effects and performing routine laboratory tests.

The purpose of the study is to see whether ZL-1310 works better than the standard therapy in shrinking tumors and helping patients live longer. Participants will be randomly assigned to receive either the new medication or the standard treatment, and they will receive the assigned therapy in repeated cycles while doctors monitor their health and any side effects. The study will track how long the cancer stays under control and how long participants live, using simple check‑ups and scans.

Participants will take the assigned tablet every day for about 48 weeks, with regular clinic visits. At each visit, a heart ultrasound called an echocardiogram will be used to measure how wide the valve opens, and a breathing‑exercise test will assess peak VO2, which reflects the maximum amount of oxygen the body can use during intense activity. A low‑dose CT scan without contrast will look at the amount of calcium on the valve. The study also tracks whether participants need a valve replacement procedure, either a catheter‑based approach (TAVR) or open‑heart surgery (SAVR), or experience any serious health events.

The purpose of the trial is to find out how different amounts of the medicine affect the return of skin color on the face. The study is a double‑blind, randomized, dose‑ranging trial in its Phase IIb stage, meaning participants are randomly assigned to receive either the medicine at one of several doses or the placebo, and neither the participants nor the study staff know which treatment is given.

Participants receive the assigned injection at regular visits over several months, with check‑ups at about 12, 24, 36 and 48 weeks to see how the skin color changes and to monitor safety. The trial looks for improvements in the amount of pigment returning to the face and records any side effects that may occur during the study period.

The purpose of the trial is to find out whether the medicine can improve lung function and reduce the number of worsening episodes. Enrolled participants will be randomly assigned to one of the two groups and will take part for about a year, with regular clinic visits where breathing tests, questionnaires about symptoms, and safety checks are performed.

At each visit, a simple breathing test called FEV1 will be done; this measures the amount of air a person can force out in one second. The study will also track how often participants experience ECOPD, which are flare‑ups that may require extra treatment or hospitalization, and will record changes in quality‑of‑life scores. Any side effects or health changes will be monitored throughout the study.

The purpose of the research is to find out whether giving a pre‑emptive dose of rituximab when the blood test shows a return of ANCA (antibodies that often signal a flare) is more effective than simply checking the patient’s health and blood work every three months. Success is measured by staying in remission, which means a disease‑activity score called BVAS remains at zero, indicating no active disease.

During the roughly two‑year follow‑up, participants will have regular clinic visits for assessments and blood tests. Those in the early‑treatment group will receive an additional rituximab infusion if ANCA reappears, while the monitoring group will continue with routine check‑ups without immediate retreatment. Throughout the study, researchers will record any relapses, side effects, and overall health using questionnaires such as the HAQ and SF-36, as well as a damage‑assessment tool called VDI. All participants will continue their low‑dose prednisolone regimen as needed.

The purpose of the study is to evaluate whether the new medicine can lower the number of treated bleeds compared with standard therapy. Participants will be assigned to receive either the new medicine or the standard factor VIII for about six months, attending regular visits where any bleeding events are recorded, quality‑of‑life questionnaires are completed, and safety checks such as blood tests for antibodies or reactions at the injection site are performed. The trial will monitor how often injections are needed, the amount of medicine used, and any side effects that arise during the treatment period.

During the study, participants will be assigned to receive either depemokimab or a placebo through a subcutaneous injection, which is a shot given just under the skin. The study is designed so that neither the participants nor the researchers know which treatment is being administered. This approach helps ensure that the results are as accurate as possible.

Participants in the study will receive an injection of a solution called Radelumin, which contains a substance that helps highlight areas of cancer during the PET/CT scan. The study will compare the results of the PET/CT scans with the findings from a biopsy, which is a procedure where a small sample of tissue is taken from the body to be examined under a microscope. This comparison will help determine the accuracy of the PET/CT scans in identifying cancer spread.

The study will be conducted over a period of time, during which participants will undergo the PET/CT scan and have their results analyzed by three independent experts who are not aware of the patients’ clinical information. This approach ensures an unbiased assessment of the imaging technique’s effectiveness. The study aims to provide valuable information that could improve the diagnosis and treatment planning for patients with high-risk prostate cancer.